Print Page  |  Close Window

PRESS RELEASE

<< Back
Brooks Automation Reports Results for the Fiscal Third Quarter of 2017, Ended June 30, 2017

CHELMSFORD, Mass., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Brooks Automation, Inc. (Nasdaq:BRKS), a leading worldwide provider of automation and cryogenic solutions for multiple markets, including semiconductor manufacturing and life sciences, today reported financial results for the third quarter of 2017, ended June 30, 2017.

Fiscal Third Quarter of 2017 Financial and Operational Highlights:

  • Revenue was $181.7 million, 23% higher compared to Q3 2016 and 7% higher than Q2 2017;
  • Life Sciences Systems segment revenue grew 26% compared to Q3 2016, to $36.8 million;
  • GAAP Net Income was $17.4 million with diluted EPS of $0.25;
  • Non-GAAP Net Income was $25.4 million with diluted EPS of $0.36; and
  • Cash flow from operations was $18.1 million, accumulating year to date to $61.4 million.

Summary of GAAP and Non-GAAP Earnings

                 
  Quarter Ended
  June 30,    March 31,    June 30, 
Dollars in thousands, except per share data 2017   2017   2016
GAAP net income $  17,350   $  14,005   $  8,564
GAAP diluted earnings per share $  0.25   $  0.20   $  0.12
                 
Non-GAAP net income $  25,353   $  19,839   $  11,128
Non-GAAP diluted earnings per share $  0.36   $  0.28   $  0.16

A reconciliation of non-GAAP measures to the most nearly comparable GAAP measures follows the consolidated balance sheets, statements of operations and statements of cash flows included in this release.

Management Comments
“The third quarter can be summarized as high growth, record gross margins, and strong cash flow,” commented Steve Schwartz, CEO of Brooks Automation.  “Performance in both segments reflects a portfolio built for the market and excellence in operational execution. Semiconductor customers turn to us as the automation source for the industry.  Life Science customers recognize Brooks as the single comprehensive solution for all of their sample management needs.  Our success has brought additional opportunities and we are winning consistently in each space.”

“The Life Science business momentum continues and we are very pleased with the recent acquisition of Pacific Bio-Material Management, Inc.,” continued Steve Schwartz. “The integration of more than 250 biotech, pharma, clinical and research customers into our Brooks storage services platform provides a broader base for continued growth.”

GAAP Summary
Revenue for the third quarter of fiscal 2017 increased 7% sequentially to $181.7 million compared to the second quarter of fiscal 2017. The growth was driven by an 8% increase in Brooks Semiconductor Solutions Group segment and a 6% increase in Brooks Life Science Systems segment. Gross margin was 39.4%, up 130 basis points from the second quarter of fiscal 2017.  Operating expenses of $52.8 million increased 6%, or $3.1 million, from the previous quarter driven primarily by M&A and consulting expenses. In the third quarter, the Company incurred $0.8 million of restructuring charges compared to $0.9 million in the second quarter. GAAP net income in the quarter was $17.4 million and diluted earnings per share was $0.25, which increased $0.05 from the second quarter.

The amortization of intangible assets, restructuring charges, impact of purchase price accounting adjustments, charges related to M&A and special charges are appropriately included in the GAAP summary of earnings discussed above. The impact on earnings of such non-GAAP adjustments is referenced in the unaudited table included within this press release.

In the following analysis of the non-GAAP results, Brooks adjusted the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A to provide investors better perspective on the results of operations, which the Company believes is more comparable to the similar analysis provided by its peers. Brooks also excludes special charges or gains, such as impairment losses, gains or losses from the sale of assets, as well as other gains and charges that are assessed to not be representative of the normal operations of the business. Brooks currently includes a valuation allowance reserve against U.S. deferred tax assets in its GAAP results. In assessing the appropriate tax rate for the non-GAAP results, the Company evaluated the adjustments discussed above and concluded it was appropriate to maintain the valuation allowance reserve in deriving the non-GAAP tax rate.

Results of Q3 Fiscal 2017 (Non-GAAP Discussion)
Non-GAAP net income was $25.4 million in the third quarter resulting in non-GAAP diluted earnings per share of $0.36 in the third quarter.   The non-GAAP diluted earnings per share is 27% higher than the second quarter of fiscal 2017 and 125% higher than the third quarter of fiscal 2016.

As noted above, revenue for the third quarter of fiscal 2017 was $181.7 million, up 7% compared to the second quarter of 2017.  The Semiconductor Solutions segment revenue increased 8% to $145.0 million, driven by strength in cryogenic pumps, automation robots and systems, and services.  Contamination Control Solutions revenue, as previously projected, was lower in the third quarter compared to the second quarter.  Life Sciences segment revenue grew 6% sequentially to $36.8 million, driven by growth in both systems and BioStorage services revenue.

Adjusted gross margin, which excludes amortization and purchase accounting impacts, was 40.0% in the third quarter, up 100 basis points from the prior quarter.  The Semiconductor Solutions segment adjusted gross margin was 40.5% in the third quarter compared to 38.7% in the prior quarter reflecting improved margins in both Automation and Contamination Control Solutions.  The Life Sciences segment adjusted gross margin was 38.0% in the third quarter compared to 40.1% in the second quarter, with margin softness in both BioStorage services and the systems business.  Within BioStorage services, the storage margins held flat compared to the second quarter, but a higher mix of genomic services provided an unfavorable impact.  In summary, the total adjusted gross profit increased by $6.7 million compared to the prior quarter, driven by $12 million higher revenue across both segments and improved gross margins in the Semiconductor Solutions segment.

Bookings for the Semiconductor Solutions segment in the third quarter totaled $131.1 million, compared to $171.6 million in the second quarter.  Backlog for the segment finished at $111 million, $14 million below the second quarter ending backlog, significantly driven by lower Contamination Control Solutions backlog.  The Life Sciences segment booked a total of $42.2 million of new contract value in the third quarter, compared to $48.1 million in the second quarter.  Year to date, Life Sciences new contract value has totaled $154 million compared to $114 million in the same period of 2016.

Non-GAAP operating expenses of $45.0 million in the third quarter of fiscal 2017 increased 1%, or $0.4 million, sequentially over the prior quarter, reflecting a 5% increase in R&D expenses and a 1% decrease in SG&A expense.

Adjusted EBITDA was $36.7 million in the third quarter, which improved by 19% from the second quarter.  The Semiconductor Solutions segment reported non-GAAP segment operating profit of $26.8 million, which was 18.5% of revenue. The Life Sciences segment reported non-GAAP operating profit of $1.6 million, 4.4% of revenue.

Cash flow from operations was $18.1 million in the third quarter.  The Company's cash, cash equivalents, and marketable securities totaled $119.7 million at the end of the quarter, compared to $110.1 million at end of the second quarter.  On July 5, 2017, the Company acquired Pacific-Bio Material Management, Inc., a provider of storage and cold-chain logistics services for biological sample materials, for $34.3 million, net of cash acquired and subject to customary working capital adjustments. 

Quarterly Cash Dividend
The Company announced that the Board of Directors has reiterated a dividend of $0.10 per share payable on September 29, 2017 to stockholders of record on September 8, 2017. Future dividend declarations, as well as the record and payment dates for such dividends, are subject to the final determination of the Company's Board of Directors.

Guidance for Fourth Fiscal Quarter 2017
The Company announced revenue and earnings guidance for the fourth quarter of fiscal 2017. Revenue is expected to be in the range of $172 million to $178 million and non-GAAP diluted earnings per share is expected to be in the range of $0.27 to $0.31. GAAP diluted earnings per share for the fourth quarter is expected to be in the range of $0.17 to $0.21, reflecting the impact of amortization, purchase price accounting and anticipated restructuring charges.

Conference Call
Brooks management will webcast its third quarter earnings conference call today at 4:30 p.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed.

The call will be broadcast live over the Internet and, together with presentation materials referenced on the call, will be hosted at the Investor Relations section of Brooks' website at www.brooks.com, and will be archived online on this website for convenient on-demand replay. In addition, you may call 888-225-2734 (US & Canada only) or 303-223-2691 to listen to the live webcast.

About Brooks Automation, Inc.
Brooks is a leading worldwide provider of automation and cryogenic solutions for multiple markets, including semiconductor manufacturing and life sciences. Brooks' technologies, engineering competencies and global service capabilities provide customers speed to market and ensure high uptime and rapid response, which equate to superior value in their mission-critical controlled environments.  Since 1978, Brooks has been a leading partner to the global semiconductor manufacturing market as a provider of precision automation and cryogenic vacuum solutions.  Since 2011, Brooks has applied its automation and cryogenics expertise to meet the sample storage needs of customers in the life sciences industry.  Brooks' life sciences offerings include a broad range of products and services for on-site infrastructure for sample management in temperatures of ‑20°C to -150°C, as well as comprehensive outsource service solutions across the complete life cycle of biological samples including collection, transportation, processing, storage, protection, retrieval and disposal.  Brooks is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia. For more information, visit www.brooks.com.

“Safe Harbor Statement” under Section 21E of the Securities Exchange Act of 1934
Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Brooks' financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. These forward-looking statements include, but are not limited to statements about our revenue and earnings expectations, our ability to increase our profitability, our ability to improve or retain our market position, and our ability to deliver financial success in the future. Factors that could cause results to differ from our expectations include the following:  the volatility of the industries the Company serves, particularly the semiconductor industry; our possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality; the inability of customers to make payments to us when due; the timing and effectiveness of cost reduction and cost control measures; price competition; disputes concerning intellectual property; uncertainties in global political and economic conditions, and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, current reports on Form 8-K and our quarterly reports on Form 10-Q. As a result we can provide no assurance that our future results will not be materially different from those projected. Brooks expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. Brooks undertakes no obligation to update the information contained in this press release.

CONTACTS:
Lynne Yassemedis
Brooks Automation
978.262.2400
lynne.yassemedis@brooks.com

John Mills
Partner
ICR, LLC
646.277.1254
john.mills@icrinc.com


BROOKS AUTOMATION, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(In thousands, except per share data)
                       
  Three Months Ended   Nine Months Ended
  June 30,    June 30, 
  2017     2016     2017     2016  
Revenue                      
Products $  141,957     $  111,596     $  396,684     $  302,238  
Services    39,760        35,938        114,321        100,532  
  Total revenue    181,717        147,534        511,005        402,770  
Cost of revenue                      
Products    85,658        69,557        243,360        192,816  
Services    24,487        23,814        74,606        68,437  
  Total cost of revenue    110,145        93,371        317,966        261,253  
Gross profit    71,572        54,163        193,039        141,517  
Operating expenses                      
Research and development    11,958        12,819        34,148        39,208  
Selling, general and administrative    40,016        31,854        109,496        98,667  
Restructuring charges    828        996        2,663        9,807  
  Total operating expenses    52,802        45,669        146,307        147,682  
Operating income (loss)    18,770        8,494        46,732        (6,165 )
Interest income    137        55        432        310  
Interest expense    (93 )      (37 )      (286 )      (56 )
Gain on settlement of equity method investment    —        —        1,847        —  
Other loss, net    (314 )      (107 )      (848 )      (289 )
Income (loss) before income taxes and equity in earnings of equity method investments    18,500        8,405        47,877        (6,200 )
Income tax provision    3,680        220        9,900        75,070  
Income (loss) before equity in earnings of equity method investments    14,820        8,185        37,977        (81,270 )
Equity in earnings of equity method investments    2,530        379        7,249        1,248  
Net income (loss) $  17,350     $  8,564     $  45,226     $  (80,022 )
Basic net income (loss) per share $  0.25     $  0.12     $  0.65     $  (1.17 )
Diluted net income (loss) per share    0.25        0.12        0.64        (1.17 )
Dividend declared per share    0.10        0.10        0.30        0.30  
                       
Weighted average shares outstanding used in computing net income (loss) per share:                      
Basic    69,711        68,628        69,496        68,437  
Diluted    70,405        69,166        70,198        68,437  
                       

BROOKS AUTOMATION, INC.
CONSOLIDATED BALANCE SHEETS
(unaudited)
(In thousands, except share and per share data)

           
  June 30,    September 30,
   2017      2016  
Assets          
Current assets          
Cash and cash equivalents $  117,081     $  85,086  
Marketable securities    12        39  
Accounts receivable, net    120,752        106,372  
Inventories    105,304        92,572  
Prepaid expenses and other current assets    22,215        15,265  
Total current assets    365,364        299,334  
Property, plant and equipment, net    52,949        54,885  
Long-term marketable securities    2,565        6,096  
Long-term deferred tax assets    1,460        1,982  
Goodwill    210,609        202,138  
Intangible assets, net    75,458        81,843  
Equity method investments    32,628        27,273  
Other assets    5,738        12,354  
Total assets $  746,771     $  685,905  
Liabilities and Stockholders' Equity          
Current liabilities          
Accounts payable $  49,991     $  41,128  
Deferred revenue    33,062        14,966  
Accrued warranty and retrofit costs    7,646        6,324  
Accrued compensation and benefits    21,718        21,254  
Accrued restructuring costs    1,690        5,939  
Accrued income taxes payable    10,466        7,554  
Accrued expenses and other current liabilities    20,686        22,628  
Total current liabilities    145,259        119,793  
Long-term tax reserves    1,782        2,681  
Long-term deferred tax liabilities    2,950        2,913  
Long-term pension liabilities    2,469        2,557  
Other long-term liabilities    4,539        4,271  
Total liabilities    156,999        132,215  
Commitments and contingencies          
Stockholders' Equity          
Preferred stock, $0.01 par value, 1,000,000 shares authorized, no shares issued or outstanding          
Common stock, $0.01 par value- 125,000,000 shares authorized, 83,216,169 shares issued and 69,754,300 shares outstanding at June 30, 2017, 82,220,270 shares issued and 68,758,401 shares outstanding at  September 30, 2016    832        821  
Additional paid-in capital    1,867,645        1,855,703  
Accumulated other comprehensive income    15,000        15,166  
Treasury stock at cost - 13,461,869 shares    (200,956 )      (200,956 )
Accumulated deficit    (1,092,749 )      (1,117,044 )
Total stockholders' equity    589,772        553,690  
Total liabilities and stockholders' equity $  746,771     $  685,905  
               


BROOKS AUTOMATION, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(In thousands)
           
           
  Nine Months Ended
  June 30, 
  2017     2016  
Cash flows from operating activities          
Net income (loss) $  45,226     $  (80,022 )
Adjustments to reconcile net income (loss) to net cash provided by operating activities:          
Depreciation and amortization    20,649        21,320  
Gain on settlement of equity method investment    (1,847 )      —  
Stock-based compensation    11,081        8,206  
Amortization of premium on marketable securities and deferred financing costs    24        368  
Undistributed earnings of equity method investments    (7,249 )      (1,248 )
Deferred income tax provision    498        71,875  
Gain on disposal of long-lived assets    (106 )      —  
Changes in operating assets and liabilities, net of acquisitions:          
Accounts receivable    (14,644 )      2,862  
Inventories    (12,851 )      2,110  
Prepaid expenses and other current assets    (6,076 )      (3,909 )
Accounts payable    9,470        (4,689 )
Deferred revenue    17,875        7,171  
Accrued warranty and retrofit costs    1,299        (87 )
Accrued compensation and tax withholdings    279        (6,558 )
Accrued restructuring costs    (4,201 )      3,720  
Accrued expenses and other current liabilities    1,954        (5,010 )
   Net cash provided by operating activities    61,381        16,109  
Cash flows from investing activities          
Purchases of property, plant and equipment    (6,827 )      (9,414 )
Purchases of technology intangibles    (240 )      —  
Purchases of marketable securities    —        (12,901 )
Sales and maturities of marketable securities    3,590        139,388  
Acquisitions, net of cash acquired    (5,346 )      (125,498 )
Disbursement for a loan receivable    —        (1,491 )
Purchases of other investments    (170 )      (500 )
   Net cash used in investing activities    (8,993 )      (10,416 )
Cash flows from financing activities          
Proceeds from issuance of common stock    960        948  
Payment of deferred financing costs    (27 )      (508 )
Common stock dividends paid    (20,932 )      (20,613 )
   Net cash used in financing activities    (19,999 )      (20,173 )
Effects of exchange rate changes on cash and cash equivalents    (394 )      (126 )
Net increase (decrease) in cash and cash equivalents    31,995        (14,606 )
Cash and cash equivalents, beginning of period    85,086        80,722  
Cash and cash equivalents, end of period $  117,081     $  66,116  
           
Supplemental disclosure of non-cash investing activities:          
Purchases of property, plant and equipment included in accounts payable $  1,009     $  1,245  
Fair value of non-cash consideration for the acquisition of Cool Lab, LLC    10,348        —  
               

Notes on Non-GAAP Financial Measures:

These financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusted the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers. Management also excludes special charges and gains, such as impairment losses, gains and losses from the sale of assets, as well as other gains and charges that are not representative of the normal operations of the business. Brooks currently includes a valuation allowance reserve against U.S. deferred tax assets in its GAAP results. In assessing the appropriate tax rate for non-GAAP results, the Company evaluated the adjustments discussed above and concluded it was appropriate to maintain the valuation allowance reserve in establishing the non-GAAP tax rate. Management strongly encourages investors to review our financial statements and publicly-filed reports in their entirety and not rely on any single measure.

                                   
  Quarter Ended
  June 30, 2017   March 31, 2017   June 30, 2016
      per diluted       per diluted       per diluted
Dollars in thousands, except per share data $   share   $   share   $   share
GAAP net income $  17,350     $  0.25     $  14,005     $  0.20     $  8,564     $  0.12  
Adjustments:                                  
Purchase accounting impact on inventory and contracts acquired    71        0.00        382        0.01        125        —  
Amortization of intangible assets    4,330        0.06        4,355        0.06        3,837        0.06  
Restructuring charges    828        0.01        860        0.01        996        0.01  
Gain on sale of a building    —        —        —        —        (55 )      —  
Merger costs    3,654        0.05        936        0.01        84        —  
Tax effect of adjustments    (880 )      (0.01 )      (699 )      (0.01 )      (2,423 )      (0.04 )
Non-GAAP adjusted net income    25,353        0.36        19,839        0.28        11,128        0.16  
  Stock based compensation, pre-tax    4,197              4,386              1,637        
  Tax rate    15   %          17   %          20   %    
Stock-based compensation, net of tax    3,559        0.05        3,641        0.05        1,318        0.02  
Non-GAAP adjusted net income - excluding stock-based compensation $  28,912     $  0.41     $  23,480     $  0.33     $  12,446     $  0.18  
                                   
Shares used in computing non-GAAP diluted net income per share          70,405              70,149              69,166  
                                               


                       
  Nine Months Ended
  June 30, 2017   June 30, 2016
      Per Diluted       Per Diluted
Dollars in thousands, except per share data $   Share   $   Share
GAAP net income (loss) $  45,226     $  0.64     $ (80,022 )   $  (1.17 )
Adjustments:                      
Purchase accounting impact on inventory and contracts acquired    523        0.01        499        0.01  
Amortization of intangible assets    12,743        0.18        11,153        0.16  
Restructuring charges    2,663        0.04        9,807        0.14  
Gain on sale of a building    —              (55 )      (0.00 )
Merger costs    4,839        0.07        3,295        0.05  
Less: Fair value adjustment of equity investment    (1,847 )      (0.03 )      —        —  
Add: True-up of BioCision stub period adjustment    203              —        —  
Establishment of valuation allowance against deferred tax assets                79,340        1.16  
Tax effect of adjustments    (1,856 )      (0.03 )      (6,723 )      (0.10 )
Non-GAAP adjusted net income    62,494        0.89        17,294        0.25  
Stock-based compensation, pre-tax    11,081              8,206        
Tax rate    16   %          24   %    
Stock-based compensation, net of tax    9,330     $  0.13        6,237        0.09  
Non-GAAP adjusted net income - excluding stock-based compensation $  71,824     $  1.02     $  23,531     $  0.34  
                       
Shares used in computing non-GAAP diluted net income per share         70,198              68,437  
                               


                                   
  Quarter Ended 
  June 30, 2017   March 31, 2017   June 30, 2016
Dollars in thousands $     $     $  
GAAP gross profit/gross margin percentage $  71,572   39.4   $  64,524   38.1   $  54,163   36.7
Adjustments:                                  
Amortization of completed technology    1,051   0.6      1,061   0.6      1,083   0.7
Purchase accounting impact on inventory and contracts acquired    71   0.0      382   0.2      125   0.1
Non-GAAP adjusted gross profit/gross margin percentage $  72,694   40.0   $  65,967   39.0   $  55,371   37.5
                                   


                       
  Nine Months Ended
  June 30, 2017   June 30, 2016
Dollars in thousands $       $  
GAAP gross profit/gross margin percentage $  193,039   37.8   $  141,517   35.1
Adjustments:                      
Amortization of completed technology    3,105   0.6      3,097   0.8
Purchase accounting impact on inventory and contracts acquired    523   0.1      499   0.1
Non-GAAP adjusted gross profit/gross margin percentage $  196,667   38.5   $  145,113   36.0
                       


                             
  Quarter Ended   Nine Months Ended
  June 30,    March 31,    June 30,    June 30,    June 30, 
Dollars in thousands 2017     2017     2016     2017     2016  
GAAP net income (loss) $  17,350     $  14,005     $  8,564     $  45,226     $  (80,022 )
Adjustments:                            
Less: Interest income    (137 )      (227 )      (55 )      (432 )      (310 )
Add: Interest expense    93        97        37        286        56  
Add: Income tax provision    3,680        3,420        220        9,900        75,070  
Add: Depreciation    2,589        2,623        3,633        7,907        10,167  
Add: Amortization of completed technology    1,051        1,061        1,083        3,105        3,097  
Add: Amortization of customer relationships and acquired intangible assets    3,279        3,294        2,754        9,638        8,056  
Earnings before interest, taxes, depreciation and amortization $  27,905     $  24,273     $  16,236     $  75,630     $  16,114  
                                       


                             
  Quarter Ended   Nine Months Ended
  June 30,    March 31,    June 30,    June 30,    June 30, 
Dollars in thousands 2017   2017   2016     2017     2016  
Earnings before interest, taxes, depreciation and amortization $  27,905   $  24,273   $  16,236     $  75,630     $  16,112  
Adjustments:                            
Less: Fair value adjustment of equity method investment    —                (1,847 )      
Add: Stock-based compensation    4,197      4,386      1,637        11,081        8,206  
Add: Restructuring charges    828      860      996        2,663        9,807  
Add: BioCision stub period adjustment    —                203        
Add: Purchase accounting impact on inventory and contracts acquired    71      382      125        523        499  
Less: Gain on sale of a building            (55 )            (55 )
Add: Merger costs    3,654      936      84        4,839        3,295  
Adjusted earnings before interest, taxes, depreciation and amortization $  36,655   $  30,837   $  19,023     $  93,092     $  37,864  
                                   


                             
  Quarter Ended   Nine Months Ended
  June 30,    March 31,    June 30,    June 30,    June 30, 
Dollars in thousands 2017     2017     2016     2017     2016  
GAAP selling, general and administrative expenses $  40,016     $  37,518     $  31,854     $  109,496     $  98,667  
Adjustments:                            
Less: Amortization of customer relationships and acquired intangible assets    (3,279 )      (3,294 )      (2,754 )      (9,638 )      (8,056 )
Less: Merger costs    (3,654 )      (936 )      (84 )      (4,839 )      (3,295 )
Non-GAAP adjusted selling, general and administrative expenses $  33,083     $  33,288     $  29,016     $  95,019     $  87,316  
Research and development expenses $  11,958     $  11,345     $  12,819     $  34,148     $  39,208  
Non-GAAP adjusted operating expenses $  45,041     $  44,633     $  41,835     $  129,167     $  126,524  
                                       


                             
  Quarter Ended   Nine Months Ended
  June 30,    March 31,    June 30,    June 30,    June 30, 
Dollars in thousands 2017   2017   2016   2017   2016
GAAP equity in earnings of equity method investments $  2,530   $  2,777   $  379   $  7,249   $  1,248
Adjustments:                            
Add: BioCision stub period adjustment                203    
Non-GAAP adjusted equity in earnings of equity method investments $  2,530   $  2,777   $  379   $  7,452   $  1,248
                             


                                   
  Brooks Semiconductor Solutions Group   Brooks Life Science Systems
  Quarter Ended   Quarter Ended
  June 30,    March 31,    June 30,    June 30,    March 31,    June 30, 
Dollars in thousands 2017   2017   2016   2017   2017   2016
GAAP gross profit $  58,083   $  51,325   $  42,904   $  13,489   $  13,199   $  11,259
Adjustments:                                  
Amortization of completed technology    626      626      711      425      435      372
Purchase accounting impact on inventory and contracts acquired    —      125      125      71      257      —
Non-GAAP adjusted gross profit $  58,709   $  52,076   $  43,740   $  13,985   $  13,891   $  11,631
                                   


                       
  Brooks Semiconductor Solutions Group   Brooks Life Science Systems
  Nine Months Ended   Nine Months Ended
  June 30,    June 30,    June 30,    June 30, 
Dollars in thousands 2017   2016   2017   2016
GAAP gross profit $  154,877   $  114,506   $  38,162   $  27,011
Adjustments:                      
Amortization of completed technology    1,879      2,005      1,226      1,093
Purchase accounting impact on inventory and contracts acquired    125      500      398    
Non-GAAP adjusted gross profit $  156,881   $  117,011   $  39,786   $  28,104
                       


                                   
  Brooks Semiconductor Solutions Group   Brooks Life Science Systems
  Quarter Ended   Quarter Ended
  June 30,    March 31,    June 30,    June 30,    March 31,    June 30, 
Dollars in thousands 2017   2017   2016   2017   2017   2016
GAAP gross margin  40.1    38.1    36.2    36.7    38.1    38.7
Adjustments:                                  
Amortization of completed technology  0.4    0.5    0.6    1.2    1.3    1.3
Purchase accounting impact on inventory and contracts acquired  —    0.1    0.1    0.2    0.7  
Non-GAAP adjusted gross margin  40.5    38.7    36.9    38.0    40.1    40.0
                                   


                       
  Brooks Semiconductor Solutions Group   Brooks Life Science Systems  
  Nine Months Ended   Nine Months Ended  
Dollars in thousands June 30, 2017   June 30, 2016   June 30, 2017   June 30, 2016  
GAAP gross margin  38.1    35.1    36.4    35.3
Adjustments:                      
Amortization of completed technology  0.5    0.6    1.2    1.4
Purchase accounting impact on inventory and contracts acquired    0.2    0.4  
Non-GAAP adjusted gross margin  38.6    35.9    38.0    36.8
                       


                                                     
  Brooks Semiconductor Solutions Group   Brooks Life Science Systems   Total Segments
  Quarter Ended   Quarter Ended   Quarter Ended
  June 30,    March 31,    June 30,    June 30,    March 31,    June 30,    June 30,    March 31,   June 30, 
Dollars in thousands 2017   2017   2016   2017   2017   2016   2017   2017   2016
GAAP operating profit (loss) $  26,188   $  20,003   $  13,119   $  1,134   $  1,290   $  (736 )   $  27,322   $  21,293   $  12,383
Adjustments:                                                    
Amortization of completed technology    626      626      711      425      435      372        1,051      1,061      1,083
Purchase accounting impact on inventory and contracts acquired    —      125      125      71      257      —        71      382      125
Non-GAAP adjusted operating profit (loss) $  26,814   $  20,754   $  13,955   $  1,630   $  1,982   $  (364 )   $  28,444   $  22,736   $  13,591
                                                       


                                                     
  Total Segments   Corporate   Total
  Quarter Ended   Quarter Ended   Quarter Ended
  June 30,    March 31,   June 30,    June 30,    March 31,   June 30,    June 30,    March 31,   June 30, 
Dollars in thousands 2017   2017   2016   2017   2017   2016   2017   2017   2016
GAAP operating profit (loss) $  27,322   $  21,293   $  12,383   $  (8,552 )   $  (6,492 )   $  (3,889 )   $  18,770   $  14,801   $  8,494
Adjustments:                                                    
Amortization of completed technology    1,051      1,061      1,083      —        —        —        1,051      1,061      1,083
Amortization of customer relationships and acquired intangible assets    —      —      —      3,279        3,294        2,754        3,279      3,294      2,754
Restructuring charges    —      —      —      828        860        996        828      860      996
Purchase accounting impact on inventory and contracts acquired    71      382      125      —        —        —        71      382      125
Merger costs    —      —      —      3,654        936        84        3,654      936      84
Non-GAAP adjusted operating profit (loss) $  28,444   $  22,736   $  13,591   $  (791 )   $  (1,402 )   $  (55 )   $  27,653   $  21,334   $  13,536
                                                           


                                   
  Brooks Semiconductor Solutions Group   Brooks Life Science Systems   Total Segments
  Nine Months Ended   Nine Months Ended   Nine Months Ended
Dollars in thousands June 30, 2017   June 30, 2016   June 30, 2017   June 30, 2016   June 30, 2017   June 30, 2016
GAAP operating profit (loss) $  63,562   $  22,717   $  2,535   $  (7,555 )   $  66,097   $  15,162
Adjustments:                                  
Amortization of completed technology    1,879      2,005      1,226      1,093        3,105      3,097
Purchase accounting impact on inventory and contracts acquired    125      500      398      —        523      500
Non-GAAP adjusted operating profit (loss) $  65,566   $  25,222   $  4,159   $  (6,462 )   $  69,725   $  18,759
                                     


                                   
  Total Segments   Corporate   Total
  Nine Months Ended   Nine Months Ended   Nine Months Ended
Dollars in thousands June 30, 2017   June 30, 2016   June 30, 2017   June 30, 2016   June 30, 2017   June 30, 2016
GAAP operating profit (loss) $  66,097   $  15,162   $  (19,365 )   $  (21,327 )   $  46,732   $  (6,165 )
Adjustments:                                  
Amortization of completed technology    3,105      3,097      —        —        3,105      3,097  
Amortization of customer relationships and acquired intangible assets    —      —      9,638        8,056        9,638      8,056  
Restructuring charges    —      —      2,663        9,807        2,663      9,807  
Purchase accounting impact on inventory and contracts acquired    523      500      —        —        523      500  
Merger costs    —      —      4,839        3,295        4,839      3,295  
Non-GAAP adjusted operating profit (loss) $  69,725   $  18,759   $  (2,225 )   $  (169 )   $  67,500   $  18,590  
                                         

 

Primary Logo

Brooks Automation, Inc.